Hydantoin

Hydantoin

SCHEMBL5185641

O=C1CNC(=O)N1.O=C1COC(=O)N1.O=C1CSC(=O)N1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 2/20 0.48
GSK3B P49841 2/20 0.48
MGAM O43451 1/20 0.48
GAA P10253 1/20 0.48
SI P14410 1/20 0.48
MGAM2 Q2M2H8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiazolidinedione SCHEMBL6598441 0.87 GSK3A (0.64) GSK3AGSK3BMGAMGAASI
Hydantoin SCHEMBL11044399 0.85 GSK3A (0.67) GSK3AGSK3BMGAMGAASI
Hydantoin SCHEMBL5655845 0.72 GSK3A (0.53) GSK3AGSK3BMGAMGAASI
Thiazolidinedione SCHEMBL8759425 0.70 GSK3A (0.59) GSK3AGSK3BMGAMGAASI
Thiazolidinedione SCHEMBL4828229 0.70 GSK3A (1.00) GSK3AGSK3BMGAMGAASI
SCHEMBL4119295 0.70
SCHEMBL123971 0.70
Thiazolidinedione SCHEMBL5043 0.70
Thiazolidinedione SCHEMBL4895522 0.70
SCHEMBL962066 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756049-A1 METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES Sanofi-Aventis Deutschland GmbH (DE) 2007-02-28 EP disclosed
WO-2005113496-A1 METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (US) 2005-12-01 WO disclosed
EP-1456187-A4 N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES INCYTE SAN DIEGO INC (US) 2005-02-09 EP disclosed
EP-1456187-A1 N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES Incyte San Diego Incorporated (US) 2004-09-15 EP disclosed
WO-2003043998-A1 N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES INCYTE SAN DIEGO INCORPORATED (US) 2003-05-30 WO disclosed